Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PROTHENA CORP PUBLIC LTD CO Director's Dealing 2021

Sep 10, 2021

32782_dirs_2021-09-10_3ec240f0-5693-433e-bc84-48aa29bc4a3a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK: 0001559053
Period of Report: 2021-09-09

Reporting Person: Karp Carol D. (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-09-09 Ordinary Shares, par value $0.01 per share M 10000 $15.04 Acquired 10000 Direct
2021-09-09 Ordinary Shares, par value $0.01 per share S 5458 $71.4477 Disposed 4542 Direct
2021-09-09 Ordinary Shares, par value $0.01 per share S 4542 $72.6299 Disposed 0 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-09-09 Stock Option (Right to Buy) $15.04 M 10000 Disposed 2028-06-21 Ordinary Shares (10000) Direct

Footnotes

F1: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: The transaction was executed in multiple trades in prices ranging from $70.94 to $71.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3: The transaction was executed in multiple trades in prices ranging from $72.16 to $72.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F4: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on June 21, 2019 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.